Antares Pharma (AMEX: AIS) reported earnings on March 12. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Antares Pharma beat expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share improved to zero.

Gross margins contracted, operating margins increased, and net margins improved.

Revenue details
Antares Pharma reported revenue of $5.4 million. The four analysts polled by S&P Capital IQ wanted to see revenue of $4.9 million on the same basis. GAAP reported sales were 65% higher than the prior-year quarter's $3.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0. The four earnings estimates compiled by S&P Capital IQ predicted $0 per share. GAAP EPS contracted to zero from the prior-year quarter's -$0.02.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 60.5%, 1,260 basis points worse than the prior-year quarter. Operating margin was -3.0%, 3,430 basis points better than the prior-year quarter. Net margin was -2.8%, 3,680 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $5.1 million. On the bottom line, the average EPS estimate is $0.

Next year's average estimate for revenue is $24.2 million.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 158 members out of 166 rating the stock outperform, and eight members rating it underperform. Among 21 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 18 give Antares Pharma a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Antares Pharma is outperform, with an average price target of $3.

The healthcare investing landscape is littered with also-rans and a few major winners. Is Antares Pharma performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.